Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Lexaria Bioscience Corp (LXX.CN)

Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets ACCESS Newswire - Mon Jul 5, 2021

KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Announces 2021 Annual Meeting Results ACCESS Newswire - Tue Jun 29, 2021

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs ACCESS Newswire - Tue Jun 15, 2021

DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Provides Progress Report on Six R&D Programs ACCESS Newswire - Wed Jun 9, 2021

- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1 ACCESS Newswire - Mon Jun 7, 2021

- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus ACCESS Newswire - Thu Jun 3, 2021

KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever ACCESS Newswire - Thu May 20, 2021

- New formulation delivers up to 2,708% more CBD into bloodstream* - Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted ACCESS Newswire - Wed May 12, 2021

- New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX)...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET ACCESS Newswire - Fri May 7, 2021

Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE / May...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 ACCESS Newswire - Thu May 6, 2021

- Up to 2,178% more CBD delivered into bloodstream* - Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)

Barchart Exclusives

As Taiwan Semi Hikes Its Dividend 20%, Should You Buy TSM Stock? Barchart - Wed Jan 21, 6:30PM CST
Taiwan Semiconductor continues to increase its payout. Is the growth sustainable? Here's what to know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot